Acutaas Chemicals Ltd · NSE:ACUTAAS
Acutaas Chemicals — Ami Organics — Q3 FY22 Earnings Presentation
33 slides from Acutaas Chemicals's earnings presentation, Feb 8, 2022
Slide 1: Exchange filing cover letter
4A© Ami Organics Limited CIN No. : L24100GJ2007PLC051093 Registered Office :- Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India. February 08, 2022 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India Lim
Slide 2: Investor Presentation February 2022
F EBR U ARY - 2 0 2 2 Investor Presentation Ami Organics Limited BSE: 543349 | NSE: AMIORG | WWW.AMIORGANICS.COM 1
Slide 3: AMI Organics agenda
AMI Organics 01. Q3 and 9M FY22 Results 02. A Specialty Chemicals Company… …Supporting innovations 03. as well as assisting Pharmaceuticals, Agrochemicals and Fine Chemical industry to improve the life of an ordinary person Our niche products, track record of working with innovators, high focus on R
Slide 4: Q3 and 9M FY22 Results contents
AMI Organics 01. Q3 and 9M FY22 Results ▪ Management Commentary ▪ Q3 & 9MFY22 Earnings Highlights 02. A Specialty Chemicals Company… ▪ Strong financial …Supporting innovations performance (Q3 FY22) 03. as well as assisting Pharmaceuticals, Agrochemicals and Fine Chemical industry to improve the life
Slide 5: Management Commentary
Management Commentary “I am happy to report that our 9M FY22 revenue grew by 52% on YoY basis Revenue for driven by robust growth in core Pharma Intermediary business as well as 9M FY22 stronger grow in Specialty Chemicals business. Our gross margin also saw improvement as compared to 9M FY21. The E
Slide 6: Q3 & 9M FY22 Earnings Highlights
Q3 & 9M FY22 Earnings Highlights Financial Highlights ✓ Revenue from operations for Q3FY22 grew by 53.5% YoY to Rs.1,412mn ✓ 9MFY22 Revenue from operations grew by 52.0% YoY to Rs. 3,766mn ✓ Gross margin for the 9M FY22 improved to 48.8% higher by 238 bps when compared to 9M FY21 numbers ✓ EBITDA fo
Slide 7: Strong financial performance (Q3 FY22)
Strong financial performance (Q3 FY22) Revenue from Operations Q3FY21 Q3FY22 (Rs Mn) FY19-21 CAGR: 27% 136% -41% 34% 1,404 1,048 835 899 290 36 28 67 Advance Intermediates Chemicals Others Total EBITDA & EBITDA Margin PAT EPS (Rs Mn) (Rs Mn) EBITDA EBITDA Margin PAT PAT Margin EPS 350 23.6% 25.0% 21
Slide 8: Strong financial performance (9M FY22)
Strong financial performance (9M FY22) Revenue from Operations 9MFY21 9MFY22 (Rs Mn) FY19-21 CAGR: 37% 234% 27% 51% 3,736 2,882 2,445 2,177 686 155 113 167 Advance Intermediates Chemicals Others Total EBITDA & EBITDA Margin PAT EPS (Rs Mn) (Rs Mn) EBITDA EBITDA Margin PAT PAT Margin EPS 23.0% 900 24
Slide 9: P&L for Q3 and 9M FY22
P&L for Q3 and 9M FY22 Particulars (Rs. Mn) Q3FY22 Q3FY21 YoY Q2FY22 QoQ 9MFY22 9MFY21 YoY Revenue from Operations 1,412 920 53.5% 1223 15.4% 3766 2477 52.0% COGS 714 466 53.4% 569 25.6% 1927 1326 45.3% Gross Profit 698 454 53.6% 654 6.6% 1839 1151 59.8% Gross Margin 49.4% 49.4% 53.5% 48.8% 46.5% Em
Slide 10: Company Overview contents
AMI Organics ▪ Company Overview 01. Q3 and 9M FY22 Results ▪ Our Journey 02. A Specialty Chemicals Company… ▪ Products and their Application ▪ Our Manufacturing Facilities …Supporting innovations ▪ Superior R&D Capabilities 03. as well as assisting Pharmaceuticals, Agrochemicals and Fine Chemical in
Slide 11: A Specialty Chemicals Company - Overview
A Specialty Chemicals Company - Overview AMI Organics (AMI) is a research and development driven manufacturer of specialty chemicals with varied end usage and is focused on the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated and generic a
Slide 12: Our Journey
Our Journey ▪ Obtained certifications for ISO 9001:2015 and ISO 14001:2015 ▪ Received second EIR from ▪ Established a tertiary ETP to USFDA for manufacturing become zero liquid discharge facility at Sachin plant ▪ Increased ▪ Commencement of a new warehouse capacity, R&D lab at Sachin ▪ Received rec
Slide 13: Our Products and their Application
Our Products and their Application Pharma Intermediates ▪ Our Company has an experience of over 15 years of developing, manufacturing Historical Business Performance and commercializing advanced pharma intermediates used for manufacturing API and NCE in India and overseas. We have developed and comm
Slide 14: Our Products and their Application (Cont'd)
Our Products and their Application (Cont’d) Advance Pharma Intermediates – Strong and Diversified portfolio with robust market standing Therapy / API Key Pharma Intermediate(s) supplied by Ami Organics Global Market Share Disease Targeted ▪ 1-(3-Chloro Phenyl)4-(3-Chloro Propyl)Piperazine H Trazodon
Slide 15: Our Products and their Application (Cont'd)
Our Products and their Application (Cont’d) Specialty Chemicals ▪ Existing portfolio: Historical Business Performance KSM for Fine Chemicals/ Specialty Chemicals ▪ Recent acquisition: 166 Products (Rs Mn) In line with Company’s inorganic growth strategy of foraying further into the specialty chemica
Slide 16: Our Manufacturing Facilities
Our Manufacturing Facilities… Manufacturing Total Land Area Installed Facilities Total (sq mtrs) 75,892 Capacity (MTPA) 6,060 Placeholder for warehouse picture Placeholder for facility picture Placeholder for facility picture Placeholder for facility picture Sachin Unit Ankleshwar Unit Jhagadia Unit
Slide 17: Superior R&D Capabilities
Superior R&D Capabilities R&D Expenditures ▪ R&D facility certified and approved ▪ 2,200 sq mtrs DSIR approved in-house R&D Rs. 24mn Rs. 86mn Rs. 65mn by DSIR of India. facility at Sachin supported by an ADL 4.0% ▪ Equipped with state-of-the-art ▪ 8 Process Patents filed in India equipment and syste
Slide 18: Strong and Long-term relations with Diversified Customers across Geographies
Strong and Long-term relations with Diversified Customers across Geographies Clientele Revenue from Exports Exports Revenue as % of Key Exports Destinations Revenue from Operations Europe 50% 46% 52% Israel Japan North America China (Rs mn) 1,757 India South America Others 27% Italy 1,183 35% 1,100
Slide 19: Our Leadership
Our Leadership Board of Directors Nareshkumar Patel Chetankumar Vaghasia Virendra Mishra Girikrishna Maniar Richa Goyal Hetal Gandhi Executive Chairman, MD Whole-time Director Whole-time Director Non-executive, Non-executive, Non-executive Independent Director Independent Director Independent Direct
Slide 20: Strengthening our Board
Strengthening our Board New Board of Directors New members joins our Board, and we believe this will further strengthen our Board Dr. Anita Bandyopadhyay Mr. Ram Mohan Rao Locande Independent Director Independent Director ▪ Dr. Anita Bandyopadhyay is an acclaimed HR consultant with extensive ▪ Mr. R
Slide 21: Aiding pharmaceuticals and agrochemicals contents
AMI Organics 01. Q3 and 9M FY22 Results ▪ Aiding pharmaceuticals companies in bettering lives 02. A Specialty Chemicals Company… ▪ Supporting Agrochemicals and Fine Chemicals …Supporting innovations companies in improving 03. as well as assisting Pharmaceuticals, Agrochemicals and lives Fine Chemica
Slide 22: Aiding pharmaceuticals companies in bettering lives
Aiding pharmaceuticals companies in bettering lives Currently ~90% of our revenue come from …with Global API industry estimated to grow by …whereas Key APIs for which Intermediates are products used in Pharmaceutical industry 6%; witnessing shift in production activity from manufactured by AMI are e
Slide 23: Supporting Agrochemicals and Fine Chem companies in improving lives
Supporting Agrochemicals and Fine Chem companies in improving lives Our existing Chemicals segment supplies KSMs to Agrochemicals and Fine Chemicals company … KSMs Global KSM Market – Size and Growth India KSM Market – Size and Growth (USD Bn) (USD Bn) 40 8.0 CAGR 6.1% CAGR 10.6% CAGR 30 6.1% CAGR 4
Slide 24: Supporting Agrochem and Fine Chem companies (Cont'd)
Supporting Agrochem and Fine Chem companies in improving lives(Cont’d) …whereas our new acquired units manufactures preservatives along with some specialty chemicals such as salicylic acid Parabens Salicylic Acid Global Paraben Market – Global Paraben Market – Global Salicylic Acid Market – Global S
Slide 25: AMI Organics
AMI Organics 01. Q3 and 9M FY22 Results 02. A Specialty Chemicals Company… …Supporting innovations 03. as well as assisting Pharmaceuticals, Agrochemicals and Fine Chemical industry to improve the life of an ordinary person Our niche products, track record of working with innovators, high focus on R
Slide 26: Our competitive advantage
Our competitive advantage Niche Product Portfolio with strong ▪ Niche products with limited competition focused on Chronic disease market 1 market share ▪ Our key products holds more than 50% market share globally Successful track record of working ▪ Ami has established itself as a trusted and relia
Slide 27: AMI Organics
AMI Organics 01. Q3 and 9M FY22 Results 02. A Specialty Chemicals Company… …Supporting innovations 03. as well as assisting Pharmaceuticals, Agrochemicals and Fine Chemical industry to improve the life of an ordinary person Our niche products, track record of working with innovators, high focus on R
Slide 28: Our Financial performance over the years
Our Financial performance over the years… Revenue from Operations(1) – Growth Trends (Rs Mn) FY19-21 CAGR: 22% 174% 17% 20% 3,406 3,011 FY19 FY20 FY21 2,385 2,396 2,034 2,179 329 229 22 74 166 143 Pharma Intermediates Speciality Chemicals Others Total Revenue – by Business Verticals Revenue from Exp
Slide 29: Our Financial performance over the years
Our Financial performance over the years… EBITDA and EBITDA Margins (%) PAT and PAT Margins (%) (Rs Mn) EBITDA (₹ Mn) EBITDA Margin (%) (Rs Mn) PAT (₹ Mn) PAT Margin (%) 23.5% 900 25.0% 600 15.9% 18.0% 800 16.0% 700 17.6% 17.1% 802 20.0% 500 540 14.0% 11.5% 600 15.0% 400 9.8% 12.0% 500 10.0% 300 400
Slide 30: Financials for last three years
Financials for last three years Restated Summary Statement of Profit and Loss Restated Summary Statement of Assets and Liabilities Particulars (Rs. Mn) FY19 FY20 FY21 Particulars (Rs. Mn) FY19 FY20 FY21 I. ASSETS Revenue from Operations 2,385 2,396 3,406 NON-CURRENT ASSETS Other Income 4 28 14 Prope
Slide 31: Shareholder Information
Shareholder Information AMI Shareholding as on 31st December 2021 Share Information (as on 31st December 2021) NSE Ticker AMIORG BSE Ticker 543349 Market Cap (Rs. Cr) 3,892 Promoters 41.5% Total Debt (Rs. Cr) 0.7 Others (Shares pledged – Nil) 49.4% Cash & Cash Equivalents (Rs. Cr) 116 Shares Outstan
Slide 32: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 33: Thank You
For more information please contact: Ami Organics Limited Ekta Srivastava, Company Secretary & Compliance Officer cs@amiorganics.com Christensen Advisory Rahul Thakur rthakur@christensenir.com Thank You © 2020 Ami Organics Limited, All Rights Reserved. 32